CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：NK cell therapy in relapsed refractory multiple myeloma.
NK cell therapy in relapsed refractory multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
近年来，过继性细胞疗法的进展在很大程度上改变了癌症免疫治疗的范式。尽管当前的免疫疗法可以治愈许多多发性骨髓瘤（MM）患者，但复发/难治性MM（RR/MM）在某些情况下仍然具有挑战性。自然杀伤（NK）细胞是先天免疫细胞，对骨髓瘤细胞等恶性细胞发挥有效的细胞毒性活性。除了抗肿瘤特性外，NK细胞在移植后不会诱导移植物抗宿主病。因此，它们为治疗RR/MM患者提供了一种有前景的方法。目前，已尝试大规模生产符合良好生产规范（GMP）的NK细胞。来自患者自身或异体供者的体外扩增/激活NK细胞是MM中NK细胞治疗的潜在选择。此外，新型细胞产品如NK细胞系和嵌合抗原受体（CAR）-NK细胞可能为NK细胞治疗提供现成的来源。在此，我们总结了NK细胞在MM微环境中的活性，并重点关注针对MM患者的不同NK细胞治疗方法。
Recent advances in adoptive cell therapy have considerably changed the paradigm of cancer immunotherapy. Although current immunotherapies could cure many patients with multiple myeloma (MM), relapsed/refractory MM (RR/MM) is still challenging in some cases. Natural killer (NK) cells are innate immune cells that exert effective cytotoxic activity against malignant cells like myeloma cells.
In addition to their antitumor properties, NK cells do not induce graft versus host disease following transplantation.
Therefore, they provide a promising approach to treating RR/MM patients. Currently, attempts have been made to produce large-scale and good manufacturing practices (GMP) of NK cells. Ex vivo expanded/activated NK cells derived from the own patient or allogenic donors are potential options for NK cell therapy in MM. Besides, novel cell-based products such as NK cell lines and chimeric antigen receptor (CAR)-NK cells may provide an off-the-shelf source for NK cell therapy.
Here, we summarized NK cell activity in the MM microenvironment and focused on different NK cell therapy methods for MM patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。
